Chief Executive Officer
President
Chief Financial Officer and Chief Operating Officer
General Counsel and Secretary
Senior Vice President of Finance/Operations and Chief Accounting Officer
Chief Scientific Officer
Chief Medical Officer
Senior Vice President, Regulatory and Quality
Senior Vice President, Corporate Business Development
Senior Vice President, Investor Relations and Corporate Communications
Senior Vice President, Clinical Development
Senior Vice President, Technical Operations
Vice President, Clinical Operations
Vice President, Safety Assessment
Vice President, Chemical Sciences
Chairman
Founder, Morphic Therapeutic
Director
Director
Director
Director
Director
Director
Director
Founder, Morphic Therapeutic
Morphic is leveraging its structural biology expertise and medicinal chemistry capabilities to develop small molecule therapeutic candidates against non-integrin targets including TL1-A and IL-23. Inhibition of these pathways have potential as treatments for IBD through monotherapy and possibly in combination with other IBD treatment mechanisms including α4β7 inhibition.
Morphic is developing small molecule inhibitors of the integrin αvβ8 for potential uses in myelofibrosis and a combination immuno-oncology approach for the treatment of solid tumors. αvβ8 is known to activate selective isoforms of TGF-β and Morphic has demonstrated that αvβ8 inhibition can drive increased platelet production and potentiate immune checkpoint blockade and potentially drive responses in checkpoint refractory tumors. Morphic’s αvβ8 inhibitors are in preclinical development.